In this blog, we will take a closer look at saRNA vaccines who offer potential advantages to conventional RNA vaccines due to their ability to self-replicate. These include a reduced effective dosage and decreased manufacturing costs. Did we spike your interest? Learn more about the three major types of RNA vaccine and the four pillars required for the successful design and development of saRNA vaccines in our most recent Zon blog.

New Tool Enables Rational Design of CRISPR-Cas9 Base Editors

Novel mRNA Vaccine Protects Against Malaria in Mice

CRISPR-Cas base editors have been limited by a lack of tools for designing and ranking the DNA targeting component, single-guide RNA (sgRNA). To address this need, researchers at the University of Minnesota recently developed a modular platform termed SpliceR and used it to compare gene disruption approaches in T cells. Read more about how TriLink's BE4, ABE7.10, and SpCas9 mRNA was used for this research.

In 2018, there were an estimated 228 million malaria cases and 405,000 deaths worldwide. mRNA vaccines are a promising approach to get the spread of this disease under control, especially following recent successes in tackling COVID-19. Read more about how TriLink's PfCSP mRNA construct has recently helped researchers with important experiments in mice.

TriLink is proud sponsor of the upcoming GEN webinar Therapeutic Advances Using In Vivo CRISPR Genome Editing.

In this webinar, Dr. Laura Sepp-Lorenzino will share the company's progress in both in vivo and ex vivo genome editing approaches. In particular, she will discuss the recent advances made regarding NTLA-2001—the first-ever investigational CRISPR-Cas9 therapy candidate to be systemically delivered for the treatment of ATTR amyloidosis.

                         Thursday, September 16, 2021, 8:00 a.m. PDT

                                  （日本時間 9月17日（金） 午前0時）